Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Post-ASCT in B-Cell NHL
NCT00225212Phase 2Completed
- Sponsor
- Stanford University
- Start
- Nov 1997
- Primary completion
- Mar 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in non-Hodgkin lymphoma (NHL), sponsored by Stanford University. Started Nov 1997; status: completed.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00225212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225212.